SYT17

Across TCGA pan-cancer cohorts, SYT17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SYT17 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SYT17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYT17 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where SYT17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.445	0.799	.024	5	view →
CCRCC	DFS	Tertile	All	1.000	0.608	.016	4	view →
PDAC	DFS	Median	II,III,IV	0.624	1.000	.026	4	view →
GBM	DFS	Quartile	All	0.808	0.588	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SYT17–LUAD (DFS)

Open the LUAD breakdown →